| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Causal Model for Primary Prevention of Cardiovascular Disease: The Health Economic Model for the Primary Prevention of Cardiovascular Disease
|
Morton, Jedidiah I.
|
|
|
27 |
12 |
p. 1743-1752
|
artikel
|
| 2 |
A Systematic Literature Review and Meta-Analysis of Primary Evidence Reporting Health-State Preference Values in Chronic Hepatitis B, C, and D
|
Kaushik, Ankita
|
|
|
27 |
12 |
p. 1779-1788
|
artikel
|
| 3 |
Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data
|
Lu, Brandon
|
|
|
27 |
12 |
p. 1689-1697
|
artikel
|
| 4 |
Cost-Effectiveness of an Extended-Role General Practitioner Clinic for Persistent Physical Symptoms: Results From the Multiple Symptoms Study 3 Pragmatic Randomized Controlled Trial
|
Neilson, Aileen R.
|
|
|
27 |
12 |
p. 1710-1721
|
artikel
|
| 5 |
Cost-Effectiveness of Hepatocellular Carcinoma Surveillance Strategies in Patients With Compensated Liver Cirrhosis in the United Kingdom
|
Garay, Osvaldo Ulises
|
|
|
27 |
12 |
p. 1698-1709
|
artikel
|
| 6 |
Direct and Indirect Mapping of Assessment of Quality of Life - 6 Dimensions (AQoL-6D) Onto EQ-5D-5L Utilities Using Data From a Multicenter, Cross-Sectional Study of Malaysians With Chronic Heart Failure
|
Tan, Yi Jing
|
|
|
27 |
12 |
p. 1762-1770
|
artikel
|
| 7 |
Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study
|
Klimchak, Alexa C.
|
|
|
27 |
12 |
p. 1641-1647
|
artikel
|
| 8 |
Does Real Option Value Influence Oncologists’ Treatment Recommendations? A Survey of US Oncologists
|
Li, Meng
|
|
|
27 |
12 |
p. 1671-1678
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
27 |
12 |
p. v
|
artikel
|
| 10 |
Enhancing Patient Response to Patient-Reported Outcome Measures: Insights From a Leading Dutch University Hospital
|
van Engen, Veerle
|
|
|
27 |
12 |
p. 1753-1761
|
artikel
|
| 11 |
Evidence Quality and Health Technology Assessment Outcomes in Reappraisals of Drugs for Rare Diseases in Germany
|
Wiedmann, Lea A.
|
|
|
27 |
12 |
p. 1662-1670
|
artikel
|
| 12 |
Exploring the Association Between Surgical Out-of-Pocket Costs and Healthcare Quality Outcomes: A Retrospective Cohort Study
|
Walsan, Ramya
|
|
|
27 |
12 |
p. 1732-1742
|
artikel
|
| 13 |
Methods for Measuring and Valuing Informal Care: A Systematic Review and Meta-Analysis in Stroke
|
Das, Neha
|
|
|
27 |
12 |
p. 1789-1804
|
artikel
|
| 14 |
Practicality, Validity, and Responsiveness of Using the Proxy Version of the Child Health Utility–9 Dimensions With Children Aged 2 to 5 Years
|
Sach, Tracey H.
|
|
|
27 |
12 |
p. 1771-1778
|
artikel
|
| 15 |
Rare Diseases: Economic Evaluation and Policy Considerations
|
Rittenhouse, Brian E.
|
|
|
27 |
12 |
p. 1635-1636
|
artikel
|
| 16 |
Table of Contents
|
|
|
|
27 |
12 |
p. i-iv
|
artikel
|
| 17 |
The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study
|
van Hezik-Wester, Valérie
|
|
|
27 |
12 |
p. 1679-1688
|
artikel
|
| 18 |
The Health Benefits, Costs, and Cost-Effectiveness of Ultraorphan Drugs
|
Clifford, Katherine A.
|
|
|
27 |
12 |
p. 1656-1661
|
artikel
|
| 19 |
The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology Assessment
|
van Engen, Anke
|
|
|
27 |
12 |
p. 1722-1731
|
artikel
|
| 20 |
Three Pillars of Support for Orphan Drug Programs: Individual Valuations, Societal Valuations, and Anonymous Altruism
|
Lakdawalla, Darius N.
|
|
|
27 |
12 |
p. 1648-1655
|
artikel
|
| 21 |
Toward Patient-Centered Drug Approval for Treatment of Rare Diseases
|
Manski, Charles F.
|
|
|
27 |
12 |
p. 1637-1640
|
artikel
|
Tijdschrift beschrijving